Literature DB >> 21414621

Prevalence of low ankle-brachial index, elevated plasma fibrinogen and CRP across Framingham risk categories: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004.

Rajoo Dhangana1, Timothy P Murphy, Michael J Pencina, Abdul M Zafar.   

Abstract

OBJECTIVE: 60-80% of heart attacks or coronary-related deaths occur in individuals identified as non-high-risk per the conventional risk assessment algorithms. Abnormal ankle-brachial index (ABI), plasma fibrinogen and plasma C-reactive protein (CRP) have been shown to be associated with a higher risk of cardiovascular disease (CVD). However, comparable data have not been reported for prevalence of abnormal ABI, fibrinogen and CRP in non-high-risk population.
METHODS: We analyzed data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES), a nationally representative cross-sectional survey of the U.S. population, for 6292 men and women, aged 40 and older, without known CVD or diabetes, with available data on standard CVD risk factors, ABI, fibrinogen and CRP. The main objective was to identify proportions of individuals with abnormal ABI (ABI<0.9 in either leg), elevated fibrinogen (≥ 400 mg/dl), and elevated CRP (>3mg/l), with otherwise low or intermediate (<20%) 10-year Framingham risk score.
RESULTS: Overall prevalence of abnormal ABI, fibrinogen, and CRP was 3.6% (95% CI 3.2-4.1%), 27.4% (95% CI 23.9-31.0%) and 38.3% (95% CI 36.5-40.0%) respectively. Among those with ABI data, 91.4% were at <20% FRS, and of these only 2.7% (95% CI 2.3-3.1%, p < 0.0001) had an abnormal ABI. Among those with fibrinogen data, 90.8% were at <20% FRS, and of these 23.6% (95% CI 20.4-26.8%, p < 0.001) had elevated plasma fibrinogen. Among those with CRP data, 91.1% were at <20% FRS, and of these 34.3% (95% CI 32.7-36.0%, p = 0.0012) had an elevated CRP. Overall, 45.0% (95% CI 42.2-47.8%; p < 0.0001) had abnormal ABI, fibrinogen or CRP but low-intermediate risk.
CONCLUSION: Abnormal ABI, elevate fibrinogen and CRP are highly prevalent among individuals otherwise at low-intermediate risk. If any or all of them are shown to improve predictive ability of FRS for primary prevention, it would have a significant public health impact.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21414621     DOI: 10.1016/j.atherosclerosis.2010.10.021

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Early Markers of Atherosclerotic Disease in Individuals with Excess Weight and Dyslipidemia.

Authors:  Eduardo Menti; Denise Zaffari; Thais Galarraga; João Regis da Conceição E Lessa; Bruna Pontin; Lucia Campos Pellanda; Vera Lúcia Portal
Journal:  Arq Bras Cardiol       Date:  2016-05-03       Impact factor: 2.000

2.  Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?

Authors:  Sarah S Singh; Courtney S Pilkerton; Carl D Shrader; Stephanie J Frisbee
Journal:  BMC Public Health       Date:  2018-04-02       Impact factor: 3.295

3.  Chronic stress: a crucial promoter of cell apoptosis in atherosclerosis.

Authors:  Ling-Bing Meng; Meng-Jie Shan; Ze-Mou Yu; Jian Lv; Ruo-Mei Qi; Peng Guo; Yuan-Meng Zhang; Tao Gong
Journal:  J Int Med Res       Date:  2019-01-31       Impact factor: 1.671

4.  Lifetime Risk of Lower-Extremity Peripheral Artery Disease Defined by Ankle-Brachial Index in the United States.

Authors:  Kunihiro Matsushita; Yingying Sang; Hongyan Ning; Shoshana H Ballew; Eric K Chow; Morgan E Grams; Elizabeth Selvin; Matthew Allison; Michael Criqui; Josef Coresh; Donald M Lloyd-Jones; John T Wilkins
Journal:  J Am Heart Assoc       Date:  2019-09-10       Impact factor: 5.501

5.  The Relationship between Cardiovascular Risk Scores and Several Markers of Subclinical Atherosclerosis in an Asymptomatic Population.

Authors:  Ovidiu Mitu; Adrian Crisan; Simon Redwood; Ioan-Elian Cazacu-Davidescu; Ivona Mitu; Irina-Iuliana Costache; Viviana Onofrei; Radu-Stefan Miftode; Alexandru-Dan Costache; Cristian Mihai Stefan Haba; Florin Mitu
Journal:  J Clin Med       Date:  2021-03-01       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.